Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

Spinal Muscular Atrophy Type 3 Clinical Trial

Official title:

A Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06421831
• Other study ID #: JLJY-GC101-SMA-010
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: May 10, 2024
• Est. completion date: December 2028

Study information

• Verified date: May 2024
• Source: GeneCradle Inc
• Contact: GeneCradle, Inc China
• Phone: +8613501380583
• Email: ind[@]bj-genecradle.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.

Description:

The purpose of this trial is to evaluate safety and efficacy of gene therapy drug GC101 in SMA 3 patients. Open-label, dose-escalation clinical trials of GC101 will be conducted in multiple centers in China. GC101 will be administrated intrathecally. Short-term safety will be evaluated in 52 weeks and enter long-term follow-up study of 5 years at will. Patients will be tested at baseline and followed up at various time points. The primary analysis for efficacy will be assessed at 12 months after treatment with GC101 on the changes from baseline HFMSE (Hammersmith Functional Motor Scale Expanded) and RULM（Revised Upper Limb Module) scores for patients of age ≥ 6 years old.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 21
• Est. completion date: December 2028
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• =2 years of age on the day of signing the informed consent form;
• Genetic and clinical diagnosis of type 3 SMA with bi-allelic deletion of SMN1 of 5qSMA;
• Hammersmith Functional Motor Scale - Expanded (HFMSE) score is between 10 and 54 at screening;
• Female patients of childbearing age who are pregnant or lactating, as well as all enrolled patients (both male and female), should take effective contraceptive measures within 6 months after the treatment;
• Patients or patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.

Exclusion Criteria:

• Patient who has participated in any previous gene therapy research trials;
• Patient who has AAV9 neutralizing antibody titer =1:200;
• Patient who has received Nusinersen within 120 days and Risdiplam within 15 days before treatment;
• Patient who requires invasive or non-invasive ventilatory support averaging=16 hours/day at screening;
• SMN2 copy numbers >4;
• Patient who needs nasal or gastric tube feeding for eating;
• Patient who is positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody;
• Known allergy or hypersensitivity to prednisolone or other glucocorticosteroids or their excipients
• Severe contractures at screening that interfere with either the ability to attain/demonstrate functional measures or with the ability to receive intrathecal (IT) dosing;
• Patient who has other serious diseases, such as severe cardiovascular and cerebrovascular diseases, digestive system diseases, urinary system diseases, endocrine system diseases, hematological diseases, immune system diseases, nervous system diseases (including but not limited to epilepsy, meningitis, history of convulsions or seizures, cerebrospinal fluid circulation disorders), and mental illnesses, etc.;
• Patient with previous injuries (such as upper or lower limb fractures) or surgical operations that have not fully recovered or reached a stable state;
• Vaccination no longer than 2 weeks before treatment;
• Patient who has any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.

Related Conditions & MeSH terms

• Atrophy
• Muscular Atrophy
• Muscular Atrophy, Spinal
• Spinal Muscular Atrophy Type 3

Intervention

Genetic:
• GC101
Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken ß-actin promoter

Locations

Country	Name	City	State
China	Beijing Tiantan Hospital, Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
GeneCradle Inc

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The proportion of patients whose Clinical Global Impression (CGI) is improved at Month 12		52 weeks
Other	The proportion of patients whose Motor Function Measure (MFM) is improved or maintained at Month 12		52 weeks
Other	Change from baseline of Forced Vital Capacity (FVC) at Month 12 ( for patients > 6 years)		52 weeks
Other	Change from baseline of Forced Expiratory Volume in 1 Second (FEV1) at Month 12 ( for patients > 6 years)		52 weeks
Other	Change from baseline of Maximal Inspiratory Pressure (MIP) at Month 12 ( for patients > 6 years)		52 weeks
Other	Change from baseline of Maximal Expiratory Pressure (MEP) at Month 12 ( for patients > 6 years)		52 weeks
Other	Change from baseline of 6 minutes walk test (6MWT) at Month 12 (for ambulatory patients)	The 6MWT is used for ambulatory participants with SMA and measures the total distance walked in 6 minutes.	52 weeks
Other	Change from baseline of SMA Independence Scale (SMAIS) at Month 12	The SMA Independence Scale (SMAIS) is a self-reported questionnaire to assess the amount of assistance patients require to perform daily activities. Higher SMAIS scores indicate greater independence.; (range: 0-44).	52 weeks
Primary	Incidence of Treatment-Emergent Adverse Events	Frequency of treatment-related adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests	52 weeks
Primary	Change from baseline on Hammersmith Functional Motor Scale - Expanded (HFMSE) scores at Month 12	HFMSE consists of 33 activities that can be scored one of three ways: 0 for unable to perform, 1 for performs with modification/adaptation, and 2 for performs without modification.	52 weeks
Secondary	The proportion of patients whose HFMSE improvement = 3 points at Month 12	HFMSE =3 points:minimal clinically important differences (MCID) were considered for the outcomes:	52 weeks
Secondary	Change from baseline on Revised Upper Limb Module (RULM) scores at Month 12	RULM is a 20-item evaluation of upper limb function primarily used for those with SMA who are non-ambulatory (young children through adults).	52 weeks